A systematic review of oral fungal infections in patients receiving cancer therapy

Supportive Care in Cancer

Volumn 18, Issue 8, 2010, Pages 985-992

  Lalla, Rajesh V ^a   Latortue, Marie C ^a   Hong, Catherine H ^b   Ariyawardana, Anura ^c   D'Amato Palumbo, Sandra ^d   Fischer, Dena J ^e   Martof, Andrew ^f   Nicolatou Galitis, Ourania ^g   Patton, Lauren L ^h   Elting, Linda S ⁱ   Spijkervet, Fred K L ^j   Brennan, Michael T ^b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b CAROLINAS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PERADENIYA   (Sri Lanka)

^d UNIVERSITY OF NEW HAVEN   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^g UNIVERSITY OF ATHENS   (Greece)

^h UNIVERSITY OF NORTH CAROLINA   (United States)

ⁱ UNIVERSITY OF TEXAS   (United States)

^j UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

more..

Author keywords

Antifungal agents; Fungal colonization; Fungal infection; Oral candidiasis; Oropharyngeal candidiasis

Indexed keywords

AMIFOSTINE; AMPHOTERICIN B; CLOTRIMAZOLE; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; NYSTATIN; PLACEBO;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FUNGAL COLONIZATION; HEAD AND NECK CANCER; HEALTH CARE COST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION PREVENTION; INFECTION RISK; INTERVENTION STUDY; MOUTH HYGIENE; MOUTH INFECTION; MOUTH INFLAMMATION; MYCOSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; QUALITY CONTROL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; THRUSH; TREATMENT PLANNING;

ANTIFUNGAL AGENTS; CANDIDIASIS, ORAL; HEALTH CARE COSTS; HUMANS; NEOPLASMS; OROPHARYNX; PHARYNGEAL DISEASES; QUALITY OF LIFE; RISK FACTORS;

EID: 77956458554     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-010-0892-z     Document Type: Review

References (57)

1. Raber-Durlacher JE, Barasch A, Peterson DE, Lalla RV, Schubert MM, Fibbe WE (2004) Oral complications and management considerations in patients treated with high-dose chemotherapy. Support Cancer Ther 1:219-229
2. Fischer DJ, Epstein JB (2008) Management of patients who have undergone head and neck cancer therapy. Dent Clin North Am 52:39-60, viii
3. Epstein JB, Freilich MM, Le ND (1993) Risk factors for oropharyngeal candidiasis in patients who receive radiation therapy for malignant conditions of the head and neck. Oral Surg Oral Med Oral Pathol 76:169-174
4. Nicolatou-Galitis O, Athanassiadou P, Kouloulias V, Sotiropoulou-Lontou A, Dardoufas K, Polychronopoulou A, Gonidi M, Kyprianou K, Kolitsi G, Skarleas C, Pissakas G, Papanikolaou IS, Kouvaris J (2006) Herpes simplex virus-1 (HSV-1) infection in radiation-induced oral mucositis. Support Care Cancer 14:753-762
5. Nicolatou-Galitis O, Velegraki A, Sotiropoulou-Lontou A, Dardoufas K, Kouloulias V, Kyprianou K, Kolitsi G, Skarleas C, Pissakas G, Papanicolaou VS, Kouvaris J (2006) Effect of fluconazole antifungal prophylaxis on oral mucositis in head and neck cancer patients receiving radiotherapy. Support Care Cancer 14:44-51
6. Terai H, Shimahara M (2007) Tongue pain: burning mouth syndrome vs Candida-associated lesion. Oral Dis 13:440-442
7. Sakashita S, Takayama K, Nishioka K, Katoh T (2004) Taste disorders in healthy "carriers" and "non-carriers" of Candida albicans and in patients with candidosis of the tongue. J Dermatol 31:890-897
8. Rapoport AP, Miller Watelet LF, Linder T, Eberly S, Raubertas RF, Lipp J, Duerst R, Abboud CN, Constine L, Andrews J, Etter MA, Spear L, Powley E, Packman CH, Rowe JM, Schwertschlag U, Bedrosian C, Liesveld JL (1999) Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol 17:2446-2453
9. Consensus Statement: Oral Complications of Cancer Therapies (1990) NCI Monographs 9:3-8
10. Brennan MT, Elting LS, Spijkervet FK Systematic reviews of oral complications from cancer therapies, Oral Care Study Group, MASCC/ISOO: methodology and quality of the literature. Support Care Cancer doi: 10.1007/s00520-010-0856-3
11. Huijgens PC, Simoons-Smit AM, van Loenen AC, Prooy E, van Tinteren H, Ossenkoppele GJ, Jonkhoff AR (1999) Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology. J Clin Pathol 52:376-380
12. Menichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, Girmenia C, Barbabietola G, Pagano L, Leoni P, Specchia G, Caiozzo A, Raimondi R, Mandelli F (1999) Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebocontrolled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Clin Infect Dis 28:250-255
13. Young GA, Bosly A, Gibbs DL, Durrant S (1999) A double-blind comparison of fluconazole and nystatin in the prevention of candidiasis in patients with leukaemia. Antifungal Prophylaxis Study Group. Eur J Cancer 35:1208-1213
14. Egger T, Gratwohl A, Tichelli A, Uhr M, Stebler Gysi C, Passweg J, Pless M, Wernli M, Buser U, Wuhrmann J et al (1995) Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients. A prospective, randomized, single-center study. Support Care Cancer 3:139-146
15. Ellis ME, Clink H, Ernst P, Halim MA, Padmos A, Spence D, Kalin M, Hussain Qadri SM, Burnie J, Greer W (1994) Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis 13:3-11
16. Ellis ME, Qadri SM, Spence D, Halim MA, Ernst P, Clink H, Baillie F, De Vol EB (1994) The effect of fluconazole as prophylaxis for neutropenic patients on the isolation of Candida spp.from surveillance cultures. J Antimicrob Chemother 33:1223-1228
17. Epstein JB, Ransier A, Lunn R, Chin E, Jacobson JJ, Le N, Reece D (1996) Prophylaxis of candidiasis in patients with leukemia and bone marrow transplants. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 81:291-296
18. Epstein JB, Vickars L, Spinelli J, Reece D (1992) Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation. Oral Surg Oral Med Oral Pathol 73:682-689
19. Koc M, Aktas E (2003) Prophylactic treatment of mycotic mucositis in radiotherapy of patients with head and neck cancers. Jpn J Clin Oncol 33:57-60
20. Laverdiere M, Rotstein C, Bow EJ, Roberts RS, Ioannou S, Carr D, Moghaddam N (2000) Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. The Canadian Fluconazole Study. J Antimicrob Chemother 46:1001-1008
21. Menichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, D'Antonio D, Ricci P, Carotenuto M, Liso V, Nosari AM, Barbui T, Fasola G, Mandelli F (1994) Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. Ann Intern Med 120:913-918
22. Meunier F, Aoun M, Janssens M, Dekoster C, Paesmans M (1991) Chemoprophylaxis of fungal infections in granulocytopenic patients using fluconazole vs oral amphotericin B. Drug Investig 3:258-265
23. Mucke R, Kaben U, Libera T, Knauerhase H, Ziegler PG, Hamann D, Strietzel M (1998) Fluconazole prophylaxis in patients with head and neck tumours undergoing radiation and radiochemotherapy. Mycoses 41:421-423
24. Nicolatou-Galitis O, Sotiropoulou-Lontou A, Velegraki A, Pissakas G, Kolitsi G, Kyprianou K, Kouloulias V, Papanikolaou I, Yiotakis I, Dardoufas K (2003) Oral candidiasis in head and neck cancer patients receiving radiotherapy with amifostine cytoprotection. Oral Oncol 39:397-401
25. Nucci M, Biasoli I, Akiti T, Silveira F, Solza C, Barreiros G, Spector N, Derossi A, Pulcheri W (2000) A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis 30:300-305
26. Philpott-Howard JN, Wade JJ, Mufti GJ, Brammer KW, Ehninger G (1993) Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group. J Antimicrob Chemother 31:973-984
27. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N (1999) Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 28:331-340
28. Rozenberg-Arska M, Dekker AW, Branger J, Verhoef J (1991) A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukaemia. J Antimicrob Chemother 27:369-376
29. Schaffner A, Schaffner M (1995) Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis 172:1035-1041
30. Tollemar J, Gross N, Dolgiras N, Jarstrand C, Ringden O, Hammarstrom L (1999) Fungal prophylaxis by reduction of fungal colonization by oral administration of bovine anti-Candida antibodies in bone marrow transplant recipients. Bone Marrow Transplant 23:283-290
31. Vreugdenhil G, Van Dijke BJ, Donnelly JP, Novakova IR, Raemaekers JM, Hoogkamp-Korstanje MA, Koster M, de Pauw BE (1993) Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. Leuk Lymphoma 11:353-358
32. Winston DJ, Chandrasekar PH, Lazarus HM, Goodman JL, Silber JL, Horowitz H, Shadduck RK, Rosenfeld CS, Ho WG, Islam MZ, Buell DN (1993) Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 118:495-503
33. Belazi M, Velegraki A, Koussidou-Eremondi T, Andreadis D, Hini S, Arsenis G, Eliopoulou C, Destouni E, Antoniades D (2004) Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment. Oral Microbiol Immunol 19:347-351
34. Bergmann OJ (1996) The demonstration of candidal pseudohyphae in salivary smears as a method of early diagnosis of oral candidiasis in patients with acute myeloid leukemia. Oral Microbiol Immunol 11:362-364
35. Brown RS, Miller JH Jr, Bottomley WK (1990) A retrospective oral/dental evaluation of 92 head and neck oncology patients, before, during and after irradiation therapy. Gerodontology 9:35-39
36. Dahiya MC, Redding SW, Dahiya RS, Eng TY, Kirkpatrick WR, Coco BJ, Sadkowski LC, Fothergill AW, Waite A, Rinaldi MG, Patterson TF, Thomas CR (2003) Oropharyngeal candidiasis caused by non-albicans yeast in patients receiving external beam radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 57:79-83
37. Jham BC, Franca EC, Oliveira RR, Santos VR, Kowalski LP, da Silva Freire AR (2007) Candida oral colonization and infection in Brazilian patients undergoing head and neck radiotherapy: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103:355-358
38. Laine PO, Lindqvist JC, Pyrhonen SO, Strand-Pettinen IM, Teerenhovi LM, Meurman JH (1992) Oral infection as a reason for febrile episodes in lymphoma patients receiving cytostatic drugs. Eur J Cancer B Oral Oncol 28 B: 103-107
39. Laine PO, Lindqvist JC, Pyrhonen SO, Teerenhovi LM, Syrjanen SM, Meurman JH (1993) Lesions of the oral mucosa in lymphoma patients receiving cytostatic drugs. Eur J Cancer B Oral Oncol 29 B: 291-294
40. Leung WK, Dassanayake RS, Yau JY, Jin LJ, Yam WC, Samaranayake LP (2000) Oral colonization, phenotypic, and genotypic profiles of Candida species in irradiated, dentate, xerostomic nasopharyngeal carcinoma survivors. J Clin Microbiol 38:2219-2226
41. Magrys A, Koziol-Montewka M, Staroslawska E, Gabczynska B (2005) The prognostic and diagnostic markers of invasive candidiasis in patients during chemotherapy. Pol J Microbiol 54:207-213
42. Meurman JH, Laine P, Lindqvist C, Pyrhonen S, Teerenhovi L (1994) Effect of anticancer drugs on patients with and without initially reduced saliva flow. Eur J Cancer B Oral Oncol 30 B: 204-208
43. Paula CR, Sampaio MC, Birman EG, Siqueira AM (1990) Oral yeasts in patients with cancer of the mouth, before and during radiotherapy. Mycopathologia 112:119-124
44. Pow EH, McMillan AS, Leung WK, Kwong DL, Wong MC (2003) Oral health condition in southern Chinese after radiotherapy for nasopharyngeal carcinoma: extent and nature of the problem. Oral Dis 9:196-202
45. Ramirez-Amador V, Esquivel-Pedraza L, Mohar A, Reynoso-Gomez E, Volkow-Fernandez P, Guarner J, Sanchez-Mejorada G (1996) Chemotherapy-associated oral mucosal lesions in patients with leukaemia or lymphoma. Eur J Cancer B Oral Oncol 32 B: 322-327
46. Wahlin YB (1991) Salivary secretion rate, yeast cells, and oral candidiasis in patients with acute leukemia. Oral Surg Oral Med Oral Pathol 71:689-695
47. Walsh T (1990) Role of surveillance cultures in prevention and treatment of fungal infections. NCI Monogr 9:43-45
48. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503-535
49. Epstein J (1990) Infection prevention in bone marrow transplantation and radiation patients. NCI Monogr 9:73-85
50. Nomura K, Kawasugi K, Morimoto T (2006) Cost-effectiveness analysis of antifungal treatment for patients on chemotherapy. Eur J Cancer Care (Engl) 15:44-50
51. de Vries R, Daenen S, Tolley K, Glasmacher A, Prentice A, Howells S, Christopherson H, De Jong-van den Berg LT, Postma MJ (2008) Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections. Pharmacoeconomics 26:75-90
52. Camara RD, Jarque I, Sanz MA, Grau S, Casado MA, Sabater FJ, Carreras E (2009) Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT. Bone Marrow Transplant
53. Collins CD, Ellis JJ, Kaul DR (2008) Comparative costeffectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia. Am J Health Syst Pharm 65:2237-2243
54. Stam WB, O'Sullivan AK, Rijnders B, Lugtenburg E, Span LF, Janssen JJ, Jansen JP (2008) Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands. Eur J Haematol 81:467-474
55. Schonfeld W, Wang Cheng J, Tong KB, Seifeldin R (2008) Costeffectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation. Clin Ther 30:964-973
56. Sohn HS, Lee TJ, Kim J, Kim D (2009) Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea. Clin Ther 31:1105-1115, discussion 1066-1108
57. Cornely OA, Ullmann AJ, Karthaus M (2003) Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 101:3365-3372